GC
ENZN

Globeflex Capital’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Globeflex Capital’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-250,761
Closed -$243K – 554
2015
Q3 		$243K Buy
250,761
+150,807
+151% +$186K 0.05% 360
2015
Q2 		$120K Sell
99,954
-488
-0.5% -$622 0.02% 393
2015
Q1 		$106K Sell
100,442
-109
-0.1% -$113 0.02% 378
2014
Q4 		$110K Sell
100,551
-119
-0.1% -$125 0.02% 376
2014
Q3 		$109K Sell
100,670
-581
-0.6% -$717 0.01% 383
2014
Q2 		$105K Buy
101,251
+913
+0.9% +$870 0.01% 384
2014
Q1 		$103K Sell
100,338
-1,116
-1% -$1.15K 0.01% 357
2013
Q4 		$117K Hold
101,454
– – 0.01% 361
2013
Q3 		$170K Buy
101,454
+1,206
+1% +$2.23K 0.02% 361
2013
Q2 		$200K Buy
+100,248
New +$293K 0.03% 367

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Globeflex Capital's ENZN Position: Q4 2015 in Review

Globeflex Capital sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2015, closing a stake of 250,761 shares — an estimated $243K sold.

Globeflex Capital first reported a position in ENZN in Q2 2013 and held it in 10 quarters. The position peaked at $243K in Q3 2015. 49 funds tracked by Wall St. Rank hold ENZN as of Q4 2015.

  • Globeflex Capital reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2015 after selling out during the quarter.
  • Globeflex Capital sold 250,761 ENZON PHARMACEUTICALS INC shares in Q4 2015, an estimated $243K.
  • Globeflex Capital first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 10 quarters.
  • Globeflex Capital's ENZON PHARMACEUTICALS INC position peaked at $243K in Q3 2015.
  • 49 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2015.

Based on Globeflex Capital's 13F filing for Q4 2015, filed 10 Feb 2016.